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A substantial part of all hereditary breast cancer cases is caused by BRCA1 germline mutations. In this review, we will discuss the
insights into BRCA1 functions that we obtained from mouse models with conventional and conditional mutations in Brca1. The most
advanced models closely resemble human BRCA1-related breast cancer and may therefore be useful for addressing clinically relevant
questions.
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Breast cancer is by far the most frequent cancer in women,
accounting for over 20% of all cancer cases. Familial breast
cancers, including those associated with heterozygous germline
mutations in the major susceptibility genes BRCA1 and BRCA2,
account for 5–10% of breast cancer cases in the western world.
BRCA1 mutation carriers have a lifetime risk of about 80% for
developing breast cancer and a 40% lifetime risk for developing
ovarian cancer. Most BRCA1-associated tumours show loss of
heterozygosity (LOH) at the BRCA1 locus, leading to loss of the
wild-type allele, which is consistent with a tumour suppressor
function of BRCA1 (Narod and Foulkes, 2004).
Since the discovery of the BRCA1 gene in 1994 (Miki et al, 1994),
several genetically engineered mouse models have been generated
for studying the in vivo functions of BRCA1. Initial studies used
conventional knockout mice with germline mutations in the mouse
Brca1 gene. These conventional Brca1 mouse mutants have
enabled us to learn a lot about the biological roles of BRCA1.
Because of the embryonic lethality of homozygous animals
carrying two defective Brca1 alleles and the lack of mammary
tumour development in heterozygous mice carrying one defective
and one wild-type Brca1 allele, these models could not be used to
study the role of BRCA1 in tumorigenesis. To overcome these
problems, the investigators generated conditional Brca1 knockout
mice that enable tissue-specific inactivation of BRCA1 by Cre
recombinase-mediated deletion of one or more Brca1 exons
flanked by loxP recombination sites (Jonkers and Berns, 2002).
The most recently developed conditional Brca1 mammary tumour
models closely mimic several important aspects of human BRCA1-
associated breast cancer and therefore serve as important tools
for the development of novel therapies for this disease.
Before elaborating on the Brca1 conventional and conditional
mouse models that have been generated to date, we will discuss the
characteristics of human BRCA1-related breast cancer in more
detail.
HUMAN BRCA1-ASSOCIATED BREAST CANCER
BRCA1-associated breast tumours are mostly high-grade invasive
ductal carcinomas (IDCs) that lack expression of estrogen receptor
(ER), progesterone receptor (PR) and ERRB2/HER2, which is
referred to as ‘triple-negative’ breast cancer (Johannsson et al,
1997). Consequently, most patients with BRCA1-mutated breast
cancer do not benefit from therapeutics that target ER- or ERBB2/
HER2-expressing tumour cells. Gene expression profiling revealed
a strong resemblance between BRCA1-mutated tumours and
sporadic basal-type breast cancer (Sorlie et al, 2003). BRCA1-
related tumours commonly express basal cytokeratins (CK5, CK6,
CK14 and CK17), are highly proliferative and show pushing
margins (Foulkes et al, 2003). BRCA1-mutated tumours also show
a significantly higher degree of genomic instability than sporadic
breast cancers (Tirkkonen et al, 1997), which is likely because of
the functions of BRCA1 in cell-cycle regulation and DNA repair
(see below).
Mutations in BRCA1 are not confined to certain functional
domains, but are scattered throughout the gene (Breast Cancer
Information Core; http://research.nhgri.nih.gov/bic/). Approxi-
mately half of all BRCA1 mutations are protein-truncating or
deleterious missense mutations, whereas the pathogenic potential
of the remainder is unknown (Chenevix-Trench et al, 2006).
Mutations in the tumour suppressor gene TP53 are more
frequent in BRCA1-associated breast tumours than in sporadic
cases (Greenblatt et al, 2001), mainly because of a selective
increase in protein-truncating TP53 mutations (Holstege et al,
2009; Manie ´ et al, 2009).
INSIGHTS INTO THE BIOLOGICAL FUNCTIONS OF
BRCA1
BRCA1 has been implicated in a remarkably broad range of
cellular processes and has also been reported to interact with a
large number of different proteins. In this section, we will briefly
describe some of the known functions of BRCA1 and also review
some recent data that point towards the novel functions of BRCA1.
First, BRCA1 has been found to co-localise and interact with
proteins involved in DNA repair, such as RAD51 (Scully et al,
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involved in the maintenance of genomic stability through a
function in DNA damage repair. The direct proof for this notion
was provided by Moynahan et al (1999), who showed that BRCA1-
deficient mouse embryonic stem (ES) cells are impaired in
homology-directed repair of DNA double-strand breaks (DSBs).
Further indications for a role of BRCA1 in DNA repair are the
increased chromosomal instability and high sensitivity to DNA-
damaging agents of BRCA1-deficient cells (Kennedy et al, 2004).
Besides its role in DNA repair, BRCA1 has been implicated in
transcriptional regulation (through its interaction with RNA
polymerase II and known transcription factors), cell-cycle
progression (Deng, 2006), ubiquitination and chromatin remodelling
(Mullan et al, 2006), as well as in maintenance of X-chromosome
inactivation (Ganesan et al, 2002).
Recent work in the group of Wicha revealed that BRCA1 may
have a role in the differentiation of ER-negative stem/progenitor
cells to ER-positive luminal cells (Liu et al, 2008). Inhibition of
BRCA1 in primary breast epithelial cells by RNA interference leads
to an increase in ALDH1-positive stem/progenitor cells and a
decrease in ER-positive luminal cells. Thus, loss of BRCA1 seems
to induce a block in epithelial differentiation and expansion of the
undifferentiated stem/progenitor cell compartment. These results
might explain why most BRCA1-mutated breast tumours have an
undifferentiated basal-like phenotype.
CONVENTIONAL BRCA1 MOUSE MODELS
A range of conventional Brca1 knockout mouse models has been
generated in an attempt to study the effects of BRCA1 loss. Until
now, a total of 10 different conventional Brca1 mouse mutants
have been generated and characterised, each carrying a mutation
in a different part of the gene (Xu et al, 1999b; Evers and Jonkers,
2006; Kim et al, 2006). In contrast to women with heterozygous
BRCA1 germline mutations, none of the heterozygous Brca1 mouse
mutants developed spontaneous mammary tumours. Although the
reason for this inconsistency is still unclear, it could point to a
species difference: the lifespan of a mouse might simply be too
short or the rate of LOH might be too low for heterozygous Brca1
mice to acquire additional mutations necessary for tumour
development. Alternatively, there might be (tissue-specific)
differences in haplo-insufficiency of the heterozygous Brca1 allele
between humans and mice. Embryonic lethality is observed for
most homozygous Brca1 mouse mutants. In line with the
embryonic lethality of Brca1 mouse mutants, no homozygous
BRCA1 mutation carriers have been described (Kuschel et al,
2001).
Most homozygous Brca1 mouse mutants die at mid-gestation,
between embryonic day 7.5 and 13.5, due to reduced cellular
proliferation without signs of increased apoptosis (Evers and
Jonkers, 2006). The variation in time point and penetrance of
embryonic lethality could be a consequence of different genetic
backgrounds of various Brca1 mouse strains. However, the
differences in protein truncation and alternative splicing of Brca1
could also have an important role in the observed phenotypic
variation between these models. A comprehensive characterisation
of the regulation and function of alternative splice variants is
necessary for accurate interpretation of the different Brca1 mutant
phenotypes. Evolutionary conservation may be a good indication
for the functionality of specific splice variants. Thus far, three
Brca1 splice variants have been shown and functionally analysed in
mice: Brca1-D11 (Xu et al, 1999b; Kim et al, 2006), Brca1-Iris and
Brca1-D22 (Pettigrew et al, 2008).
Mouse embryos carrying Brca1 mutations that abolish expres-
sion of full-length Brca1 without affecting Brca1-D11 expression
survive significantly longer than embryos harbouring Brca1
mutations that abolish expression of both transcripts (Evers and
Jonkers, 2006). Mouse BRCA1-D11, similar to full-length BRCA1, is
localised in nuclear foci and shows a cell-cycle-regulated expres-
sion pattern (Huber et al, 2001). However, BRCA1-D11 is not
phosphorylated and does not promote formation of RAD51 foci
upon DNA damage. Indeed, homozygous Brca1
Tr mouse mutants
that express BRCA1-D11 are viable on a BALB/c genetic back-
ground, but develop various tumours including mammary
carcinomas after long latency (Ludwig et al, 2001). Similarly, mice
with mammary gland-specific deletion of full-length Brca1 but
retention of Brca1-D11 develop mammary adenocarcinomas
characterised by genetic instability (Xu et al, 1999a). Thus,
BRCA1-D11 may compensate for some of the functions of full-
length BRCA1 during embryogenesis, but is unable to fully execute
the functions of full-length BRCA1 in maintenance of genomic
stability and tumour suppression.
The BRCA1-IRIS transcript comprises exons 1–11 and a part of
intron 11, encoding for a protein with the same N-terminus as full-
length BRCA1, but with a unique C-terminus (Elshamy and
Livingston, 2004). BRCA1-IRIS was shown to be exclusively
chromatin associated and to have a positive influence on DNA
replication. Recently, Brca1-Iris, the mouse orthologue of human
BRCA1-IRIS, was identified (Pettigrew et al, 2008). Most BRCA1
mouse models generated to date have deleted Brca1-Iris in addition
to full-length Brca1 (Evers and Jonkers, 2006). Interestingly, the
only Brca1 mutation that disrupts full-length Brca1 and Brca1-D11
transcripts but not Brca1-Iris, causes embryonic lethality at E10.5
(Hohenstein et al, 2001), suggesting that BRCA1-IRIS cannot
compensate for the loss of full-length BRCA1 and BRCA1-D11
expression.
Pettigrew et al (2008) identified BRCA1-D22 in both human and
mouse cells. Skipping of exon 22 leads to a loss of the second BRCT
repeat and functional analysis revealed that the BRCA1-D22
protein is no longer capable of transcriptional activation. In line
with this, a Brca1 truncation mutant lacking the second BRCT
repeat shows a delayed embryonic lethality when compared with
Brca1-null mutants (Hohenstein et al, 2001).
Similar to the differences in time point and penetrance of
embryonic lethality observed for different Brca1 mouse mutants,
the rescue of embryonic lethality by loss of p53 was also subject to
phenotypic variation. In Brca1-null mutants, p53 deficiency
resulted in only a partial rescue of embryonic lethality (Hakem
et al, 1997; Ludwig et al, 1997). In hypomorphic Brca1 mutants, the
effects of a Trp53-null or Trp53-heterozygous background were
more pronounced, leading to a survival of Brca1 and Trp53
compound mutant mice to adulthood (Cressman et al, 1999; Xu
et al, 2001).
In conclusion, several Brca1 conventional mouse mutants have
been generated that show phenotypic variation, ranging from early
embryonic lethality to viable mice that develop tumours. This
phenotypic variation is likely due to the differences in expression
of BRCA1 splice variants and BRCA1-IRIS in the various Brca1
mouse mutants.
CONDITIONAL BRCA1 MOUSE MODELS
Although conventional Brca1 mouse models have enabled us to
learn a lot about the biological functions of BRCA1, the observed
embryonic lethality of homozygous animals and lack of mammary
tumour development in heterozygous mice made it difficult to
study the role of BRCA1 in tumour suppression. For this purpose,
investigators turned to conditional mouse models to study the
effects of BRCA1 loss.
To date, five different conditional Brca1 alleles have been
generated (Table 1): Brca1
F11 (Xu et al, 1999a), Brca1
F5–6 (Mak
et al, 2000), Brca1
F5–13 (Liu et al, 2007), Brca1
F22–24 (McCarthy
et al, 2007) and Brca1
F2 (Shakya et al, 2008). Although
Cre-mediated deletion completely abrogates BRCA1 function for
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F5–6, the Brca1
F5–13 and the Brca1
F22–24 allele, deletion of
exon 11 in the Brca1
F11 allele does not affect the expression of the
BRCA1-D11 isoform.
Different tissue-specific promoters were used in combination
with these conditional Brca1 alleles to achieve Cre expression in
mammary epithelium. Xu et al (1999a) used transgenic mice
expressing Cre from the whey acidic protein (WAP) or mouse
mammary tumour virus (MMTV) promoter to induce mammary-
specific recombination of the Brca1
F11 alleles. In both models,
different types of mammary tumours developed with a long latency
and these tumours showed genomic instability and altered Trp53
expression. The vast majority of these tumours were negative for
ER, but a large proportion overexpressed ERBB2 (Table 1).
Removal of one Trp53 allele significantly reduced mammary
tumour latency (Brodie et al, 2001). These results proved that
BRCA1 functions as a tumour suppressor and cooperates with
TP53 in tumorigenesis.
More evidence for interaction of BRCA1 and TP53 in
tumorigenesis was provided by our lab. We generated a condi-
tional mouse model with K14cre-mediated deletion of both Brca1
and Trp53 in several epithelial tissues, including mammary
epithelium (Liu et al, 2007). Female mice of this strain showed a
high incidence of mammary carcinomas that displayed important
hallmarks of human BRCA1-associated breast tumours: tumours
were poorly differentiated, highly proliferative, genomically
instable, ER-negative and showed an increased expression of basal
epithelial markers (Table 1).
Another mouse model for basal-like breast cancer was generated
by conditional deletion of Brca1 exons 22–24 (which harbour the
second BRCT domain) in the mammary gland by using
b-lactoglobin (BLG)-cre (McCarthy et al, 2007). When combined
with heterozygosity for a Trp53 mutation, this led to mammary
tumour formation. The resulting mammary tumours were
characterised by high histological grade, central necrotic areas
and expression of basal-like markers. In addition, they frequently
lacked expression of ER, PR and ERBB2 (Table 1). Because of their
strong resemblance to human BRCA1-related breast cancer,
especially the mouse models of Liu and McCarthy should prove
useful in preclinical therapeutic intervention studies.
BRCA1 also interacts with BARD1, a protein that is structurally
related to BRCA1 in that it contains an N-terminal RING domain
and C-terminal BRCT repeats (Wu et al, 1996). The BRCA1/BARD1
heterodimer functions as a ubiquitin E3 ligase that can target
proteins for destruction by transferring ubiquitin to these proteins
(Hashizume et al, 2001). Until recently, the role of the BRCA1/
BARD1 heterodimer in tumour suppression had not been
evaluated. To address this question, Shakya et al (2008) generated
mouse strains carrying conditional alleles of Bard1 and/or Brca1
and used Cre-mediated recombination to inactivate these genes
specifically in mammary epithelial cells. Breast tumours arising in
these conditional Bard1- and/or Brca1-mutant mice were indis-
tinguishable from each other. These findings indicate that BARD1
itself is a tumour suppressor and that the tumour suppressor
activities of BRCA1 are mediated by the BRCA1/BARD1 hetero-
dimer.
Recent experiments have shown that ES cells expressing a
ubiquitin ligase-deficient BRCA1-I26A mutant are viable and do
not undergo spontaneous chromosomal rearrangements (Reid
et al, 2008). These cells show higher levels of genomic rearrange-
ments after mitomycin C (MMC) treatment, but do not show
hypersensitivity to MMC. Brca1
I26A-mutant ES cells form RAD51
foci in response to irradiation and are capable of repairing double-
strand breaks by homologous recombination. These results suggest
that the function of BRCA1 in the maintenance of genomic stability
is not dependent on its ubiquitin ligase activity. Mouse models
carrying ubiquitin ligase-deficient Brca1 alleles should reveal
whether this activity is also dispensable for the tumour suppressor
activity of BRCA1.
CHEMOPREVENTION STUDIES IN BRCA1 MODELS
Although genetic testing for inherited BRCA1 mutations provides
valuable information to women at high risk of breast cancer,
carriers of BRCA1 mutations have few clinical options to reduce
their cancer risk. Prophylactic surgery is still one of the most
important measures of breast cancer prevention for BRCA1
mutation carriers. The rationale for antihormonal therapy as an
Table 1 Conditional Brca1 mouse models
Brca1
mutation
p53 co-
mutation
Cre
transgene
Genetic
background
Mean tumor
latency
(months)
Triple-
negative
tumours
Basal -like
tumours
Initial
platinum
sensitivity
Platinum
resistance
Initial
PARPi
sensitivity
PARPi
resistance
MMTVcre;Brca1
F11/D11
WAPcre;Brca1
F11/D11
(Xu et al, 1999a)
Brca1
D11 No MMTVcre or
WAPcre
NIH-BL(S) 413 — No
a ————
MMTVcre;
Brca1
F11/F11;p53+/ 
WAPcre;
Brca1
F11/F11;p53+/ 
(Brodie et al, 2001)
Brca1
D11 p53
Null MMTVcre or
WAPcre
NIH-BL(S),
C57BL/6, 129/
Sv
8N o
b No
a ————
WAPcre
c;Brca1
F11/F11;
p53
F5–6/F5–6
(Poole et al, 2006)
Brca1
D11 p53
D5–6 WAPcre
c C57BL/6, 129/
Sv or C57BL/6,
BALB/c
7N o
c No
a Yes Yes — —
BLGcre;
Brca1
F22–24/F22–24;
p53
+/ 
(McCarthy et al, 2007)
Brca1
D22–24 p53
Null BLGcre C57BL/6, 129/
Sv
7 Y e s Y e s ————
K14cre;
Brca1
F5–13/F5–13;
p53
F2–10/F2–10
(Liu et al, 2007)
Brca1
D5–13 p53
D2–10 K14cre FVB, 129/Ola 7 Yes Yes Yes No Yes Yes
WAPcre;Brca1
F1/F1
(Shakya et al, 2008)
Brca1
D1 No WAPcre C57BL/6, 129/
Sv
17 Yes Yes — — — Yes
Abbreviations: —¼ not determined.
aHeterogeneous mammary tumour spectrum.
bERBB2-positive and ER-negative, PR status not determined.
cPR-positive, ER and ERBB2
status not determined.
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that oophorectomy prevents breast cancer in BRCA1 mutation
carriers (Narod and Offit, 2005). These data indicate that, despite
the fact that most BRCA1-mutated tumours are ER-negative,
tumour development in BRCA1 mutation carriers is hormone
dependent. This hormone dependency might also be the reason
why BRCA1 specifically functions as a tumour suppressor in
hormone-sensitive tissues such as breast and ovaries. Although the
mechanistic basis for the hormone dependency and tissue
specificity of BRCA1-associated tumorigenesis is still unknown,
BRCA1 has been shown to interact directly with ER-a and PR and
to modulate their transcriptional activities (Fan et al, 1999; Katiyar
et al, 2006). To address the role of PR signalling in BRCA1-
mediated carcinogenesis, Poole et al (2006) made use of the
WAPcre;Brca1
F11/F11;Trp53
F5–6/F5–6 mouse model. Treatment of 3-
to 4-month-old mice with the PR inhibitor mifeprestone (RU 486)
prevented mammary tumour formation in these mice. Although
the results obtained with this conditional Brca1 mouse model hold
promise for the development of anti-progesterones as prophylactic
therapy for BRCA1-associated breast cancer, the jury is still out on
this for several reasons. First, mifeprestone is not a selective PR
antagonist because it also binds with high affinity to glucocorticoid
receptors. It is therefore possible that the prevention of mammary
tumours is (in part) caused by the antiglucocorticoid effects of
mifeprestone. Second, it is not clear whether the mammary
tumours arising in this WAPcre;Brca1
F11/F11;Trp53
F5–6/F5–6 mouse
model do or do not express ER, PR and ERBB2. The status of ER,
PR and ERBB2 could have an important role in the effectiveness of
anti-progesterone therapy. Most human BRCA1-mutated breast
cancers are ‘triple-negative’ tumours that do not express ER, PR
and ERBB2. It is unclear whether anti-progesterone therapy will
also protect against development of triple-negative breast tumours
in BRCA1-mutation carriers. It may therefore be important to
evaluate the effects of PR antagonists in Brca1 mouse models that
certainly recapitulate development of triple-negative BRCA1-
associated breast cancer.
CHEMOTHERAPEUTIC INTERVENTIONS IN BRCA1
MODELS
Breast cancers of BRCA1 mutation carriers frequently show poor
responses to neoadjuvant therapy with docetaxel, whereas
platinum-based chemotherapy seems to be highly effective (Byrski
et al, 2008, 2009). Similarly, BRCA1/2 mutation carriers with
ovarian cancer show higher response rates and longer overall
survival after platinum-based chemotherapy than nonhereditary
patients (Ben David et al, 2002; Tan et al, 2008).
Unfortunately, the experiments studying drug response and
especially drug resistance in human patients are very time
consuming. With regard to this time issue, conditional Brca1
mouse models that develop mammary tumours with strong
resemblance to human BRCA1-mutated breast tumours (Liu
et al, 2007; McCarthy et al, 2007) can be very helpful in predicting
response and resistance to conventional and targeted therapeutics.
Our K14cre;Brca1
F5–13/F5–13;Trp53
F2–10/F 2–10 mouse model was
used for studying responses to various conventional chemother-
apeutics, such as doxorubicin, docetaxel and cisplatin, and for
analysing the mechanisms of acquired resistance (Rottenberg et al,
2007). Similar to the human situation, heterogeneity in the
response of individual mouse mammary tumours was observed,
but eventually all tumours became resistant to doxorubicin and
docetaxel. The upregulation of ATP-binding cassette (ABC) drug
transporters seemed to be the main mechanism responsible for
resistance to doxorubicin. Remarkably, acquired resistance to
platinum compounds was never observed. However, the tumours
could also not be completely eradicated; even after dose-dense
platinum therapy, the tumours appeared to regrow from a small
fraction of surviving cells. Currently, these platinum-resistant
tumour remnants are being further characterised. In addition,
attempts are being made to achieve eradication of this small
fraction of surviving cells by combination therapies.
Especially intriguing is the observation that platinum resistance
is never observed in these mouse tumours, whereas resistance is a
major problem in the clinic. As described earlier, BRCA1 has an
important role in the error-free repair of double-stranded DNA
breaks that occur after platinum therapy. These mouse tumour
data raise the question whether platinum resistance can occur at all
in BRCA1-deficient tumours that are completely defective in
homology-directed DNA repair. This question became even more
evident when Swisher et al (2008) showed that acquired resistance
to platinum compounds in BRCA1-mutated human ovarian
tumours is associated with secondary mutations in BRCA1 that
restore the open-reading frame in platinum-resistant tumours.
Three out of five platinum-resistant tumours showed secondary
genetic changes in BRCA1, whereas no BRCA1 alterations were
observed in three platinum-sensitive tumours. The main difference
between the human situation and the K14cre;Brca1
F5–13/F5–13;
Trp53
F2–10/F 2–10 mouse model is that the mouse tumours have a
homozygous deletion of Brca1 exons 5–13. As a result of this large
deletion, secondary mutations in Brca1 cannot restore Brca1
function and serve as a mechanism for platinum resistance in the
mouse tumours. Together, the human and mouse data suggest that
BRCA1 not only functions as a tumour suppressor, but is also
required for development of resistance to therapy.
Intervention studies with conventional chemotherapeutics were
also carried out in WAPcre;Brca1
F11/F11;Trp53
F5–6/F5–6 and
MMTVcre;Brca1
F11/F11;Trp53
F5–6/F5–6 models (Shafee et al, 2008).
In line with data obtained from the K14cre;Brca1
F5–13/F5–13;
Trp53
F2–10/F 2–10model, Brca1
D11/D11;Trp53
D5–6/D5–6tumours also
responded better to platinum compounds than to doxorubicin.
Following initial regression, tumours relapsed at the same site at
2–3 months after treatment. Whereas platinum resistance was
never observed in the K14cre;Brca1
F5–13/F5–13;Trp53
F2–10/F 2–10
model, Shafee et al (2008) observed platinum resistance in their
Brca1
F11/F11;Trp53
F5–6/F5–6 models. After a second round of
treatment with platinum drugs, tumours recurred with a faster
growth rate. This rapid recurrence could suggest the existence of a
population of platinum-resistant cells that are selected during a
second round of platinum treatment. An important difference
between the two studies described above is that Rottenberg et al
(2007) used a mouse model with a conditional Brca1 null allele,
whereas Shafee et al (2008) used a Brca1 hypomorphic allele that
still expresses the Brca1-D11 isoform after Cre-mediated deletion
of exon 11. Furthermore, the platinum treatment regime differs
considerably between the two studies. It would be informative to
see whether Brca1
D11/D11;Trp53
D5–6/D5–6 tumours would acquire
full resistance to platinum drugs during additional rounds of
therapy and if so, by which mechanism.
INTERVENTIONS WITH TARGETED THERAPEUTICS
IN BRCA1 MODELS
Until now, targeted therapeutics are only available for ER- and
ERBB2-positive breast cancer, and no tailored therapy exists for
triple-negative breast cancer. As mentioned earlier, BRCA1
deficiency causes defects in homology-directed DSB repair. A
few years back, BRCA1/2-deficient cells were shown to be highly
sensitive to chemical inhibitors of Poly(ADP-ribose) polymerase-1
(PARP1), a key molecule in the repair of DNA single-strand
breaks (SSBs) (Farmer et al, 2005). It is thought that, upon
inactivation of SSB repair by PARP inhibition, DSBs are induced
by replication fork collapse at SSBs during S phase. Therefore,
PARP inhibition may be synthetically lethal with BRCA1 loss
and serve as a specific therapy for BRCA1-mutated tumours.
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F5–13/F5–13;Trp53
F2–10/F2–10 mouse model was
used to study the effects of PARP inhibition in a ‘realistic’ in vivo
setting (Rottenberg et al, 2008). The BRCA1-deficient tumours
arising in this model showed a prolonged response to the clinical
PARP inhibitor olaparib without signs of toxicity. Eventually, long-
term treatment with olaparib resulted in resistance as a
consequence of upregulation of the P-glycoprotein drug efflux
pump. Combining platinum therapy with PARP inhibition
increased the relapse-free survival as compared with platinum
monotherapy, suggesting that PARP inhibition enhances the
effects of DNA-damaging agents. Recently, it was shown that
olaparib has antitumour activity in patients with BRCA1- or
BRCA2-associated malignancies (Fong et al, 2009). These findings
illustrate how Brca1 conditional mouse models can be of use for
preclinical assessment of new targeted therapeutics.
NEXT-GENERATION BRCA1 MODELS
Despite the fact that current Brca1 mouse models have enabled us
to learn a lot about BRCA1 function in normal development and
tumorigenesis, improvements can still be made.
For instance, nearly all existing mouse models for BRCA1-
associated breast cancer described earlier are based on co-
mutation of Trp53 and Brca1. It might be possible that mutations
in yet other genes, such as Pten (Saal et al, 2008), are required to
effectively model BRCA1-mutated breast cancer in mice.
Current Brca1 mouse models are also not ideally suited to study
mechanisms of acquired resistance to conventional and targeted
therapeutics. Rottenberg et al (2007, 2008) showed that upregula-
tion of drug efflux pumps is the most prevalent mechanism of
acquired resistance to conventional and targeted therapies for
mammary tumours arising in the K14cre;Brca1
F5–13/F5–13;Trp53
F2–
10/F2–10 mouse model. Currently, the treatment responses in this
K14cre;Brca1
F/F;Trp53
F/F mouse model are being studied in a P-
glycoprotein-deficient background to unravel P-glycoprotein-
independent mechanisms of drug resistance (Table 2).
Mouse models based on deleterious missense or protein-
truncating Brca1 mutations that closely mimic human BRCA1
germline mutations will be useful for studying tumorigenesis,
treatment responses and acquired resistance associated with
known pathogenic BRCA1 mutations. These mouse models could,
for example, be used for studying the role of genetic reversion in
therapy resistance (Table 2). As the number of therapy-resistant
tumour samples from patients with specific BRCA1 founder
mutations is low, the mouse models carrying these mutations
could offer a larger platform to study if and how the genetic
reversion occurs as a mechanism of drug resistance for different
BRCA1 founder mutations. Eventually, insights gained from mouse
models carrying specific Brca1 mutations could lead to tailored
therapy for people with a particular BRCA1 mutation.
Another option is to study the consequences of individual
mutations in the human BRCA1 gene in vivo by creating mice that
express human BRCA1. Already in 2001 it was shown that human
BRCA1 is able to rescue embryonic lethality in Brca1 knockout
mice (Chandler et al, 2001). This shows that it may be possible to
introduce human BRCA1 BAC clones harbouring specific muta-
tions in an intact animal model system. This system would provide
the best possible in vivo analysis of the phenotypic consequences
of specific BRCA1 mutations.
CONCLUDING REMARKS
Genetically engineered mouse models for BRCA1 deficiency have
proven to be of critical importance for gathering insights on the
diverse biological functions of BRCA1, both in normal develop-
ment and tumorigenesis. In the past years, these mouse models
have been further improved to recapitulate the salient features of
human BRCA1-associated breast cancer, such as ‘triple-negative’
status, increased genomic instability and increased expression of
basal epithelial markers.
Recapitulation of these characteristics in mouse models is
crucial for preclinical development of chemoprevention strategies
and tailored therapies for BRCA1-associated breast cancer. The
first studies with targeted therapeutics in validated BRCA1 models
have been conducted, showing excellent initial responses but P-
glycoprotein-mediated drug resistance upon prolonged treatment
with the PARP inhibitor olaparib (Rottenberg et al, 2008). Of
course, it is important to keep in mind that data obtained from
mouse tumour models are not necessarily predictive for clinical
responses and acquired resistance in human cancer patients.
Although genetically engineered mice for BRCA1 deficiency are
promising preclinical models, their predictive value remains to be
determined.
The PARP inhibitor olaparib was recently evaluated in a
phase I clinical trial and showed antitumour activity in BRCA1
or BRCA2 mutation carriers with ovarian, breast or prostate
cancer (Fong et al, 2009). In this case, the mouse data did seem to
reflect the clinical response quite accurately. It will be of great
interest to see whether the acquired resistance to the PARP
inhibitor that we observe in the mouse model will also arise in the
human situation.
Of course, current mouse models are not perfect yet and can still
be further improved to closely mimic additional aspects of human
BRCA1-related breast cancer, to study, for example, the role of
genetic reversion in therapy resistance. It can be expected that the
resulting models will be of even greater use in the development of
therapies directed against various aspects of the disease.
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